Purchase this article with an account.
Caterina Gagliano, Rosario Foti, Elisa Visalli, Roberta Amato, Giuseppe Calì, Giovanni Panta, Daniela Rocca, Alessandra Pizzo, Giorgio Amato, Giulia Malaguarnera; Vitamin D in Systemic Sclerosis Patients with Dry Eye Syndrome. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5587.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to explore the clinical and pathogenic significance of vitamin D (25-hydroxyvitamin D) in systemic sclerosis (SSc) patients with dry eye syndrome (DES). The relationship between the severity of DES, SSc disease activity and levels of 25-hydroxyvitamin D was investigated.
In this cross-sectional study, 32 consecutive patients with SSc and DES were enrolled. We measured blood concentrations of 25-hydroxyvitamin D (25 OH D) and correlated the results with SSc disease activity calculated with modified Rodman Skin Score (mRSS), Tear osmolarity measurements (TearLab system), Tear Break-Up Time (TBUT) test, and Schirmer tests (type I and II).
Levels of 25 OH D were decreased in all SSc patients with DES as compared to normal controls and the reduced levels of 25 OH D were stable over the observed period of 2 months. Levels of 25 OH D correlated inversely with mRSS score and tear osmolarity (r = 0.610, p < 0.001), positively correlated with Schirmer values, (r = -0.231, p = 0.045), and TBUT values (r = -0.325, p = 0.007) among all patients.
Our study demonstrated a high relationship with SSc disease acitivity, severity of DES and low levels of 25-hydroxyvitamin D.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only